MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
475.45
+3.24
+0.69%
After Hours: 475.45 0 0.00% 19:30 09/25 EDT
OPEN
474.04
PREV CLOSE
472.21
HIGH
479.97
LOW
470.40
VOLUME
472.45K
TURNOVER
--
52 WEEK HIGH
609.35
52 WEEK LOW
409.07
MARKET CAP
20.39B
P/E (TTM)
17.01
1D
5D
1M
3M
1Y
5Y
1D
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
Seeking Alpha · 1d ago
Sell Rating Could Reshape The Case For United Therapeutics Stock (UTHR)
Simply Wall St · 1d ago
Buy/Sell: Wall Street’s top 10 stock calls this week
TipRanks · 2d ago
United Therapeutics (UTHR) Faces Yutrepia Pressure, Is It Still 29% Undervalued?
Simply Wall St · 3d ago
United Therapeutics Downgraded to Sell as Premium Valuation Clashes with Shrinking Core Business and Challenging Launch Outlook for Tyvaso and Jenraldi
TipRanks · 3d ago
Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating
NASDAQ · 3d ago
Why United Therapeutics (UTHR) Shares Are Falling Today
Barchart · 3d ago
United Therapeutics Price Target Announced at $321.00/Share by Goldman Sachs
Dow Jones · 4d ago
More
About UTHR
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.

Webull offers United Therapeutics Corp stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.